Medical Properties Trust (MPW) CEO discloses 2026 stock grants

Rhea-AI Filing Summary

Medical Properties Trust Chairman, President & CEO Edward K. Aldag Jr. reported several stock-related transactions. On January 8, 2026, he was granted 1,018,247 shares of common stock that will be earned only if specific performance thresholds for reducing overall debt and growing cash revenue are met from January 1, 2026 through December 31, 2028, with a chance to earn up to one third based on 2026 results and further adjustment based on total shareholder return. The same day he also received 1,099,707 shares of common stock that vest in equal installments at the beginning of each of 12 calendar quarters starting April 1, 2026. On January 9, 2026, 188,951 shares were withheld at $5.04 per share to cover tax obligations upon vesting of restricted stock, which is not treated as a sale. After these transactions, he directly beneficially owns 6,904,641 shares of common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aldag Edward K JR

(Last) (First) (Middle)

1000 URBAN CENTER DRIVE

SUITE 501

(Street)

BIRMINGHAM AL 35242

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MEDICAL PROPERTIES TRUST INC [ MPW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman, President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock, par value $0.001	01/08/2026		A		1,018,247(1)	A	$0	5,993,885(2)	D
Common stock, par value $0.001	01/08/2026		A		1,099,707(3)	A	$0	7,093,592	D
Common stock, par value $0.001	01/09/2026		F		188,951(4)	D	$5.04	6,904,641	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares will be earned based on the achievement of specific performance thresholds pertaining to the Company's reduction of overall debt and cash revenue growth, as defined and set by our compensation committee, over the period from January 1, 2026 through December 31, 2028, with the opportunity to earn up to one third of the award for 2026 performance against the specified measures. The actual number of shares to be issued will vary depending upon the achievement of these specific performance thresholds and further adjusted pursuant to modifier provisions in the award that are based on the Company's total return to shareholders.

2. The total amount of securities beneficially owned following the reported transaction includes a reduction of shares that were forfeited due to only partially satisfying the performance thresholds established as part of the 2023 Performance Share Award.

3. Shares vest ratably at the beginning of each of the 12 calendar quarters beginning April 1, 2026.

4. Represents shares withheld upon vesting of restricted stock to satisfy tax withholding obligations. This does not constitute a sale transaction.

	W. Zachary Riddle, by power of attorney	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider stock transactions did MPW CEO Edward K. Aldag Jr. report?

Edward K. Aldag Jr., Chairman, President & CEO of Medical Properties Trust (MPW), reported two stock grants on January 8, 2026 and a tax-withholding share transaction on January 9, 2026.

How many performance-based shares did the MPW CEO receive and what are the conditions?

He received 1,018,247 shares that will be earned based on specific performance thresholds tied to reducing overall debt and increasing cash revenue from January 1, 2026 through December 31, 2028, with potential to earn up to one third for 2026 performance and further adjustment based on total shareholder return.

What are the vesting terms for the 1,099,707 MPW shares granted to the CEO?

The 1,099,707 shares of common stock vest ratably at the beginning of each of 12 calendar quarters starting on April 1, 2026.

Were any Medical Properties Trust shares sold by the CEO in this filing?

The filing reports 188,951 shares withheld on January 9, 2026 at $5.04 per share to satisfy tax withholding upon vesting of restricted stock, and explicitly states this does not constitute a sale transaction.

How many MPW shares does the CEO beneficially own after these transactions?

Following the reported transactions, Edward K. Aldag Jr. directly beneficially owns 6,904,641 shares of Medical Properties Trust common stock.

What performance period applies to the 2026 performance share award for the MPW CEO?

The performance-based award is measured over the period from January 1, 2026 through December 31, 2028, with performance thresholds set by the company’s compensation committee.